Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 6/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102978 | 0.87 | ALDH1A1 (0.38) | ALDH1A1CES1CES2TP53LMNA | |
| SCHEMBL103877 | 0.83 | ALDH1A1 (0.40) | ALDH1A1CES1CES2TP53CA1 | |
| SCHEMBL102980 | 0.80 | CA12 (0.34) | ALDH1A1HPGD | |
| SCHEMBL8386109 | 0.80 | ALDH1A1 (0.47) | ALDH1A1CES1CES2TP53CA1 | |
| SCHEMBL103820 | 0.77 | CA12 (0.39) | ALDH1A1CES1CES2CA1KDM5A | |
| SCHEMBL29882148 | 0.74 | CYP1A2 (0.46) | ALDH1A1LMNAKDM5AKDM4C | |
| SCHEMBL103352 | 0.74 | ALDH1A1 (0.60) | ALDH1A1CES1CES2TP53CA1 | |
| SCHEMBL103889 | 0.73 | — | — | |
| SCHEMBL11770064 | 0.73 | ALDH1A1 (0.61) | ALDH1A1CES1CES2TP53CA1 | |
| SCHEMBL103666 | 0.71 | CES2 (0.38) | ALDH1A1CES1CES2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8728442-B2 | Method of controlling the growth of microorganisms by a composition containing isolated or in vitro synthesized nitrosoamides | BAYER CROPSCIENCE LP (US) | 2014-05-20 | — | — | US | disclosed |
| US-8728442-B2 | Method of controlling the growth of microorganisms by a composition containing isolated or in vitro synthesized nitrosoamides | BAYER CROPSCIENCE LP (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120058058-A1 | COMPOUNDS DERIVED FROM MUSCODOR FUNGI | AGRAQUEST, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058058-A1 | COMPOUNDS DERIVED FROM MUSCODOR FUNGI | AGRAQUEST, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058058-A1 | COMPOUNDS DERIVED FROM MUSCODOR FUNGI | SPOUT1, ERG28, DDT | ALDH1A1 1190/4885CES1 2896/4885CES2 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.